Information Provided By:
Fly News Breaks for March 25, 2019
MGTA
Mar 25, 2019 | 05:11 EDT
Goldman Sachs analyst Terence Flynn last night downgraded Magenta Therapeutics to Neutral from Buy and lowered his price target for the shares to $16 from $17. The analyst reduced his near-term estimates for MGTA-456 after the company elected to delay initiation of a Phase 2 trial in sickle cell disease. He cites valuation for the downgrade to Neutral with the shares slightly above his new price target.
News For MGTA From the Last 2 Days
There are no results for your query MGTA
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.